Medicinal composition for treating atherosclerosis

Abstract

The invention relates to a medicinal composition for treating atherosclerosis, and application of the medicinal composition. The medicinal composition comprises L-arginine, a platelet aggregation inhibitor and a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable carriers, wherein the platelet aggregation inhibitor comprises aspirin, clopidogrel, sarpogrelate and pharmaceutically acceptable salts or esters thereof. The medicinal composition can be used for preventing and / or treating atherosclerosis, and is capable of reducing morbidity and mortality rates of atherosclerosis.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a pharmaceutical composition for treating atherosclerosis and its application in preventing and / or treating atherosclerosis. Background technique [0002] Cardiovascular disease is one of the major diseases that endanger human health at present, and its high morbidity, disability and mortality have brought heavy burdens to the society and residents. Its most basic pathological process is atherosclerosis. [0003] The causes of atherosclerosis include accumulation of blood lipids, endothelial cell damage and inflammatory response. Impairment of endothelial function is the initiating link of atherosclerosis, which can reflect the severity of atherosclerosis development. Risk factors for atherosclerosis such as hyperlipidemia, hypertension, diabetes, smoking, and hyperuricemia first lead to impaired endothelial function, which is represented by endothelium-dependent vasodilation dysfunction....

AI Technical Summary

Problems solved by technology

[0012] However, there is no report on the combined use of arginine and platelet aggregation inhibitors for the treatment and / or prevention of atherosclerosis in the prior art